Scilex Holding Company Announces Acceptance of Abstract for Poster and Oral Presentation at the Annual Meeting of the American Academy of Pain Medicine (AAPM)
27 Fevereiro 2024 - 11:00AM
Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an
innovative revenue-generating company focused on acquiring,
developing and commercializing non-opioid pain management products
for the treatment of acute and chronic pain, today announced
acceptance of an abstract for poster and oral presentation at the
2024 Annual Meeting of the American Academy of Pain Medicine (AAPM)
which will take place on March 7-10, 2024 in Scottsdale, Arizona.
- Titled: Decreased Opioid Utilization with Lidocaine
Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective
Claims Analysis (First author: Srinivas Nalamachu, M.D.). Oral
Presentation Schedule: Saturday, March 9,
2024; 10:15-10:20AM (MST)
- In this retrospective analysis of OPTUM claims data, we
evaluated over 6,000 patients with neuropathic pain who were
treated with either ZTlido® or a generic lidocaine 5% patch and
were also receiving an opioid.
- The study demonstrated a greater proportion of patients treated
with ZTlido® (lidocaine topical system 1.8%) were able to either
decrease or discontinue opioids (51.9% versus 45.5%, p=0.021)
compared to patients treated with a generic lidocaine 5% patch. In
addition, patients treated with ZTlido® had a more significant
reduction in opioid dose relative to a generic lidocaine 5%
patch.
- Regardless of the type of neuropathic pain, ZTlido® was
associated with a greater opioid-sparing effect than a generic
lidocaine 5% patch.
- While a generic lidocaine 5% patch has been well established to
reduce analgesic use; this study is the first to evaluate the
opioid-sparing effect of two bioequivalent formulations of
lidocaine patches (ZTlido® and a generic lidocaine 5% patch).
- The novel design of ZTlido® has demonstrated significantly
better adhesion performance than a generic lidocaine 5% patch.
Greater adhesion provides improved medication delivery and pain
relief for patients. As a result, improved adhesion for ZTlido® is
likely contributing to more optimal pain management and enable
reduction/discontinuation of opioid dose.
- Title: Retrospective Claims Analysis of Decreased
Healthcare Visits and Costs with Lidocaine Topical System 1.8%
Compared to Lidocaine 5% Patch (First Author: Srinivas Nalamachu,
MD.) Oral Presentation Schedule: Saturday, March 9, 2024;
10:20-10:25 AM (MST)
- In a retrospective analysis of over 889,000 patients, we used
Symphony Health claims data to evaluate the impact of ZTlido®
(lidocaine topical system 1.8%) versus lidocaine 5% patch on
healthcare resource utilization, including emergency room visits,
office/clinic visits, outpatient visits, and pain procedures.
- Across the studied care settings, treatment with ZTlido® was
associated with either a reduction or insignificant increase in
healthcare resource utilization, while lidocaine 5% patch was
associated with consistently and significantly large increases in
healthcare resource utilization.
- These results are consistent with and confirm early reported
data from another retrospective claims analysis (Painweek
2023)
- This is the first study evaluating the impact on healthcare
resource utilization of two bioequivalent formulations of lidocaine
patch (ZTlido® and lidocaine 5% patch).
- The novel design of ZTlido® has demonstrated significantly
better adhesion performance than lidocaine 5% patch. Greater
adhesion provides improved medication delivery and pain relief for
patients. As a result, improved adhesion for ZTlido® is likely
contributing to more optimal pain management and may result in
reduced healthcare resource utilization.
For more information on ZTlido® including Full Prescribing
Information, refer to www.ztlido.com.
For more information on ELYXYB®, including Full Prescribing
Information, refer to www.elyxyb.com.
For more information on Gloperba®, including Full Prescribing
Information, refer to www.gloperba.com.
About Scilex Holding Company
Scilex Holding Company is an innovative revenue-generating
company focused on acquiring, developing and commercializing
non-opioid pain management products for the treatment of acute and
chronic pain. Scilex targets indications with high unmet needs and
large market opportunities with non-opioid therapies for the
treatment of patients with acute and chronic pain and are dedicated
to advancing and improving patient outcomes. Scilex’s commercial
products include: (i) ZTlido® (lidocaine topical system) 1.8%, a
prescription lidocaine topical product approved by the U.S. Food
and Drug Administration (the “FDA”) for the relief of neuropathic
pain associated with postherpetic neuralgia, which is a form of
post-shingles nerve pain; (ii) ELYXYB®, a potential first-line
treatment and the only FDA-approved, ready-to-use oral solution for
the acute treatment of migraine, with or without aura, in adults;
and (iii) GLOPERBA®, the first and only liquid oral version of the
anti-gout medicine colchicine indicated for the prophylaxis of
painful gout flares in adults, expected to launch in 2024.
In addition, Scilex has three product candidates: (i) SP-102 (10
mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXATM” or
“SP-102”), a novel, viscous gel formulation of a widely used
corticosteroid for epidural injections to treat lumbosacral
radicular pain, or sciatica for which Scilex has completed a Phase
3 study; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a
next-generation, triple-strength formulation of ZTlido, for the
treatment of chronic neck pain and for which Scilex has recently
completed a Phase 2 trial in low back pain; and (iii) SP-104 (4.5
mg, low-dose naltrexone hydrochloride delayed-release capsules)
(“SP-104”), a novel low-dose delayed-release naltrexone
hydrochloride being developed for the treatment of fibromyalgia,
for which Phase 1 trials were completed in the second quarter of
2022 and a Phase 2 clinical trial is expected to commence in
2024.
Scilex Holding Company is headquartered in Palo Alto,
California.
Forward-Looking Statements
This press release and any statements made for and during any
presentation or meeting concerning the matters discussed in this
press release contain forward-looking statements related to Scilex
and its subsidiaries under the safe harbor provisions of Section
21E of the Private Securities Litigation Reform Act of 1995 and are
subject to risks and uncertainties that could cause actual results
to differ materially from those projected. Forward-looking
statements include statements regarding the results from the
ZTlido® study and statements regarding the potential for ZTlido® to
have greater opioid sparing effects compared to generic lidocaine
patches, Scilex’s plans to launch Gloperba in 2024 and plans to
initiate Phase 2 trial in 2024 for SP-104.
Risks and uncertainties that could cause Scilex’s actual results
to differ materially and adversely from those expressed in our
forward-looking statements, include, but are not limited to: risks
associated with the unpredictability of trading markets and whether
a market will be established for Scilex’s common stock; general
economic, political and business conditions; risks related to
COVID-19 (and other similar disruptions); the risk that the
potential product candidates that Scilex develops may not progress
through clinical development or receive required regulatory
approvals within expected timelines or at all; risks relating to
uncertainty regarding the regulatory pathway for Scilex’s product
candidates; the risk that Scilex will be unable to successfully
market or gain market acceptance of its product candidates; the
risk that Scilex’s product candidates may not be beneficial to
patients or successfully commercialized; the risk that Scilex has
overestimated the size of the target patient population, their
willingness to try new therapies and the willingness of physicians
to prescribe these therapies; risks that the outcome of the trials
and studies for SP-102, SP-103 or SP-104 may not be successful or
reflect positive outcomes; risks that the prior results of the
clinical and investigator-initiated trials of SP-102 (SEMDEXA™),
SP-103 or SP-104 may not be replicated; regulatory and intellectual
property risks; and other risks and uncertainties indicated from
time to time and other risks described in Scilex’s most recent
periodic reports filed with the Securities and Exchange Commission,
including Scilex’s Annual Report on Form 10-K for the year ended
December 31, 2022 and subsequent Quarterly Reports on Form 10-Q
filed with the Securities and Exchange Commission, including the
risk factors set forth in those filings. Investors are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date of this release, and Scilex
undertakes no obligation to update any forward-looking statement in
this press release except as may be required by law.
Contacts:
Investors and MediaScilex Holding Company 960 San Antonio
RoadPalo Alto, CA 94303Office: (650) 516-4310
Email: investorrelations@scilexholding.com
Website: www.scilexholding.com
SEMDEXA™ (SP-102) is a trademark owned by Semnur
Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding
Company. A proprietary name review by the FDA is planned.
ZTlido® is a registered trademark owned by
Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex
Holding Company.
Gloperba® is the subject of an exclusive,
transferable license to use the registered trademark by Scilex
Holding Company.
ELYXYB® is the subject of an exclusive,
transferable license to use the registered trademark by Scilex
Holding Company.
All other trademarks are the property of their
respective owners.
© 2024 Scilex Holding Company All Rights
Reserved.
Scilex (NASDAQ:SCLX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Scilex (NASDAQ:SCLX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024